Ablynx promoted to the Belgian mid-cap index

20-02-2013

ABLYNX PROMOTED TO THE BELGIAN MID-CAP INDEX

GHENT, Belgium, 20 February 2013 - Ablynx [Euronext Brussels: ABLX], a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments for a range of serious human diseases, today announced its promotion to the Belgian Mid-Cap Index (Bel Mid Index or BELMID). Ablynx will be included in the BELMID Index as of the 18th of March 2013.

The entry of Ablynx to the BELMID Index is a result of performance of the Ablynx shares and is based on Ablynx’s market capitalisation, free float and liquidity in the period up to end of January 2013.

PDF-file 364.9kb

Dutch version - French version - German version